{"title":"自信地为阿片类药物使用障碍患者开处方","authors":"Alison Knopf","doi":"10.1002/cpu30890","DOIUrl":null,"url":null,"abstract":"<p>A new message from the Food and Drug Administration (FDA) encourages primary care providers to prescribe medication — primarily, buprenorphine — for opioid use disorder (OUD) “with confidence.” In the missive, subtitled “Patients with opioid use disorder need you,” the FDA noted that more than 6 million people age 12 or older have an OUD. Below is the FDA statement.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prescribe for patients with opioid use disorder — with confidence\",\"authors\":\"Alison Knopf\",\"doi\":\"10.1002/cpu30890\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A new message from the Food and Drug Administration (FDA) encourages primary care providers to prescribe medication — primarily, buprenorphine — for opioid use disorder (OUD) “with confidence.” In the missive, subtitled “Patients with opioid use disorder need you,” the FDA noted that more than 6 million people age 12 or older have an OUD. Below is the FDA statement.</p>\",\"PeriodicalId\":22496,\"journal\":{\"name\":\"The Brown University Child & Adolescent Psychopharmacology Update\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Child & Adolescent Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cpu30890\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Child & Adolescent Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpu30890","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Prescribe for patients with opioid use disorder — with confidence
A new message from the Food and Drug Administration (FDA) encourages primary care providers to prescribe medication — primarily, buprenorphine — for opioid use disorder (OUD) “with confidence.” In the missive, subtitled “Patients with opioid use disorder need you,” the FDA noted that more than 6 million people age 12 or older have an OUD. Below is the FDA statement.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
